CR20230500A - Métodos para inhibir ras - Google Patents

Métodos para inhibir ras

Info

Publication number
CR20230500A
CR20230500A CR20230500A CR20230500A CR20230500A CR 20230500 A CR20230500 A CR 20230500A CR 20230500 A CR20230500 A CR 20230500A CR 20230500 A CR20230500 A CR 20230500A CR 20230500 A CR20230500 A CR 20230500A
Authority
CR
Costa Rica
Prior art keywords
methods
inhibiting ras
ras
inhibiting
ras proteins
Prior art date
Application number
CR20230500A
Other languages
English (en)
Inventor
Robert J Nichols
Ryan B Corcoran
Original Assignee
Massachusetts Gen Hospital
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital, Revolution Medicines Inc filed Critical Massachusetts Gen Hospital
Publication of CR20230500A publication Critical patent/CR20230500A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)

Abstract

La descripción presenta métodos para inhibir proteínas RAS, por ejemplo, proteínas RAS que han adquirido resistencia a uno o más inhibidores de RAS. La descripción también utiliza métodos para el tratamiento del cáncer.
CR20230500A 2021-04-02 2022-04-01 Métodos para inhibir ras CR20230500A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170292P 2021-04-02 2021-04-02
US202163192843P 2021-05-25 2021-05-25
PCT/US2022/023133 WO2022212894A1 (en) 2021-04-02 2022-04-01 Methods for inhibiting ras

Publications (1)

Publication Number Publication Date
CR20230500A true CR20230500A (es) 2024-02-13

Family

ID=83456876

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230500A CR20230500A (es) 2021-04-02 2022-04-01 Métodos para inhibir ras

Country Status (12)

Country Link
US (1) US20240108630A1 (es)
EP (1) EP4320143A1 (es)
JP (1) JP2024512767A (es)
KR (1) KR20240004436A (es)
AU (1) AU2022249177A1 (es)
BR (1) BR112023020182A2 (es)
CA (1) CA3214155A1 (es)
CR (1) CR20230500A (es)
IL (1) IL307396A (es)
MX (1) MX2023011608A (es)
TW (1) TW202308632A (es)
WO (1) WO2022212894A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023199180A1 (en) * 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
WO2023232776A1 (en) * 2022-06-01 2023-12-07 F. Hoffmann-La Roche Ag Haloindole macrocyclic compounds for the treatment of cancer
CN117903169A (zh) * 2022-09-19 2024-04-19 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
CN118047799A (zh) * 2022-11-16 2024-05-17 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
WO2024167880A1 (en) * 2023-02-06 2024-08-15 Bicara Therapeutics Inc. Combination therapy and related methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101602876B1 (ko) * 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용

Also Published As

Publication number Publication date
KR20240004436A (ko) 2024-01-11
AU2022249177A1 (en) 2023-10-19
EP4320143A1 (en) 2024-02-14
CA3214155A1 (en) 2022-10-06
US20240108630A1 (en) 2024-04-04
IL307396A (en) 2023-12-01
MX2023011608A (es) 2023-12-14
WO2022212894A1 (en) 2022-10-06
TW202308632A (zh) 2023-03-01
BR112023020182A2 (pt) 2023-12-12
JP2024512767A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
CR20230500A (es) Métodos para inhibir ras
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CL2021000039A1 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas (divisional solicitud 201903796)
CO2020002588A2 (es) Composiciones que comprenden un inhibidor de shp2 y metodos para tratar el cáncer
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
EA202091540A1 (ru) Антитела к lilrb2
BR112018068341A2 (pt) 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
CR20160132A (es) Composiciones y método para tratar condiciones asociadas con el complemento
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112018007604A2 (pt) métodos para tratar câncer usando compostos de pirimidina e piridina com atividade inibitória de btk
CL2019002854A1 (es) Compuesto macrocíclico y sus usos.
CO2018013020A2 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
BR112018001438A2 (pt) expressão de fgfr e suscetibilidade a um inibidor de fgfr
CY1123019T1 (el) Σπειροκυκλικες ενωσεις
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
CL2017000006A1 (es) Derivados de quinolizinona como inhibidores de pi3k
BR112022010633A2 (pt) Composto de fórmula, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer de tireoide e invenção
BR112017008496A2 (pt) compostos para uso em tratamento antelmíntico
BR112018014247A2 (pt) inibição de reação alérgica usando um inibidor il-33
UY38352A (es) Inhibidores de integrina alfavbeta6